PLUR רווח נקי למניה ב-12 החודשים האחרונים Pluri Inc.
Pluri Inc. is implementing a unique 3D technology for growing placental cells to create large-scale batches of living medicines. The profit per unit trend over the last 12 months illustrates the dynamics of this process, where the value remains at -2.46. Despite pressure from traditional pharmacology, a strong team of Israeli scientists provides the company with a sustainable technological advantage in biomedicine.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_PLUR_-_Pluri-Inc._-_Earnings-per-share-for-the-last-four-quarters "Pluristem Therapeutics - רווח נקי למניה (EPS TTM) PLUR (תקופה 28.04.2023 - 13.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Pluristem Therapeutics (PLUR)
Earnings per share (EPS TTM) reflects the portion of profit attributable to a single security over the last twelve months. This metric allows for an assessment of the asset's real return by excluding the impact of the total issuance volume. By analyzing changes in the rolling annual EPS, an investor determines the business's resilience to market downturns. For Pluri Inc. (PLUR), this indicator confirms the effectiveness of commercializing cell technologies through government and agro-industrial partnerships. The synergy between biotech and foodtech directly influences the dynamics of this fundamental metric.
